Cancelled by the investigator Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)

Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029984

Enrollment

Unknown

Registered

2020-02-18

Start date

2020-03-01

Completion date

Unknown

Last updated

2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Experimental group:Routine treatment +biological preparation of human placenta

Control group:conventional therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with confirmed novel coronavirus-infected pneumonia; 2. Voluntarily sign written informed consent.

Exclusion criteria

Exclusion criteria: 1. Extremely ill patients with shock, acute respiratory distress syndrome, and multiple organ failure; 2. Pregnant or lactating women; 3. In the opinion of the investigator, previous or present illnesses may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.; 4. The investigator believes that the patient has other conditions that are not suitable for enrollment.

Design outcomes

Primary

Measure	Time frame
IFN-gama;TNF-alpha;Blood routine index;Time and rate of coronavirus become negative;immunoglobulin;Exacerbation (transfer to RICU) time;Clearance rate and time of main symptoms (fever, fatigue, cough);	—

Contacts

Public ContactWei Wei

Guangzhou reborn health management consultation co., LTD

wwei@chinacord.org+86 13729856651

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026